Host response to immune checkpoint inhibitors contributes to tumor aggressiveness

Targeted deletion of PD-1 in myeloid cells induces antitumor immunity

(2020) Laura Strauss et al.   Science Immunology

Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies

(2020) Aleksandra Filipovic et al.   Frontiers in Cell and Developmental Biology

Side effects of immunotherapy

(2019) Florian Scotté et al.   CURRENT OPINION IN ONCOLOGY

Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages

(2019) Di Lu et al.   Journal of Immunology Research

Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment

(2018) Hirotake Tsukamoto et al.   CANCER RESEARCH

Author Correction: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

(2018) Carsten Krieg et al.   NATURE MEDICINE

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent

(2018) Chloé Grasselly et al.   Frontiers in Immunology

Characterization of the role of RILP in cell migration

(2017) Azzurra Margiotta et al.   EUROPEAN JOURNAL OF HISTOCHEMISTRY

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG

(2017) Deborah T. Blumenthal et al.   NEURO-ONCOLOGY

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases

(2017) Chen Rachman-Tzemah et al.   Cell Reports

Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer

(2016) Muhammad Wasif Saif et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy

(2016) Y. Shaked et al.   CANCER RESEARCH

Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab

(2016) M. Sade-Feldman et al.   CLINICAL CANCER RESEARCH

Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy

(2016) Ofrat Beyar-Katz et al.   JOURNAL OF PATHOLOGY

Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects

(2016) Yuval Shaked   Nature Reviews Clinical Oncology

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

The prognostic landscape of genes and infiltrating immune cells across human cancers

(2015) Andrew J Gentles et al.   NATURE MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Cancer and the Immune System: Basic Concepts and Targets for Intervention

(2015) Drew Pardoll   SEMINARS IN ONCOLOGY

Dequalinium blocks macrophage-induced metastasis following local radiation

(2015) Michael Timaner et al.   Oncotarget

Intermittent Metronomic Drug Schedule Is Essential for Activating Antitumor Innate Immunity and Tumor Xenograft Regression

(2015) Chong-Sheng Chen et al.   NEOPLASIA

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

(2014) Roger Stupp et al.   LANCET ONCOLOGY

Macrophages associated with tumors as potential targets and therapeutic intermediates

(2014) Serguei Vinogradov et al.   Nanomedicine

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

(2013) Christiane Meyer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Host Response to Short-term, Single-Agent Chemotherapy Induces Matrix Metalloproteinase-9 Expression and Accelerates Metastasis in Mice

(2011) S. Gingis-Velitski et al.   CANCER RESEARCH

Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

(2011) J. E. Chaft et al.   CLINICAL CANCER RESEARCH

TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice

(2011) Abigail F. Welford et al.   JOURNAL OF CLINICAL INVESTIGATION

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents

(2008) Yuval Shaked et al.   CANCER CELL